Cytosorbents Co. (NASDAQ:CTSO) Stock Holdings Raised by Skylands Capital LLC

Skylands Capital LLC lifted its stake in shares of Cytosorbents Co. (NASDAQ:CTSO) by 10.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 3,254,213 shares of the medical research company’s stock after buying an additional 309,543 shares during the quarter. Skylands Capital LLC owned 0.07% of Cytosorbents worth $3,612,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Chicago Partners Investment Group LLC raised its stake in Cytosorbents by 84.0% during the third quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after buying an additional 16,598 shares in the last quarter. Raymond James & Associates bought a new stake in shares of Cytosorbents in the 4th quarter valued at approximately $56,000. Finally, Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CTSO has been the topic of several research analyst reports. StockNews.com assumed coverage on Cytosorbents in a research note on Wednesday, April 24th. They set a “hold” rating on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Friday, March 15th.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO traded down $0.00 during trading on Monday, hitting $0.82. 37,441 shares of the company traded hands, compared to its average volume of 152,977. The company has a quick ratio of 1.51, a current ratio of 1.77 and a debt-to-equity ratio of 0.11. The business’s fifty day moving average is $0.93 and its 200-day moving average is $1.16. The stock has a market capitalization of $44.31 million, a price-to-earnings ratio of -1.28 and a beta of 0.58. Cytosorbents Co. has a one year low of $0.78 and a one year high of $4.29.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. The business had revenue of $8.67 million during the quarter, compared to analyst estimates of $9.29 million. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. As a group, equities analysts predict that Cytosorbents Co. will post -0.36 earnings per share for the current fiscal year.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.